Temozolomide cocrystals exhibit drug sensitivity in glioblastoma cells

Abstract

Temozolomide is the only drug approved for the treatment of malignant brain tumors. The sensitivity of Temozolomide-Succinic acid and Temozolomide-Oxalic acid cocrystals (TMZ-SA and TMZ-OA) in inhibiting the proliferation and growth of human glioblastoma malignant cell lines U373, U87 and LN18 is comparable to the reference drug. Both TMZ-SA and TMZ-OA cocrystals are stable to long term storage (white color powder) whereas TMZ becomes tan brown within 2 months (indicative of degradation). These pharmaceutical cocrystals combine the desirable features of hyrolytic stability, good dissolution and cytotoxic activity for further preclinical studies. © The National Academy of Sciences, India 2014.